世界の有効性試験市場(~2027年):サービスタイプ別(抗菌/防腐有効性試験、消毒有効性試験)、用途別(製薬、化粧品&パーソナルケア、医療機器、消費財)、地域別

【英語タイトル】Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027

MarketsandMarketsが出版した調査資料(BT5932-22)・商品コード:BT5932-22
・発行会社(調査会社):MarketsandMarkets
・発行日:2022年7月19日
・ページ数:176
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥658,350見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥884,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,083,950見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
MarketsandMarkets社の最新調査レポートによると、世界の有効性試験市場規模は、2022年315百万ドルから2027年423百万ドルまで年平均6.1%拡大すると見込まれています。当書では有効性試験の世界市場を総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、サービスタイプ別(抗菌/防腐有効性試験、消毒有効性試験)分析、用途別(医薬品製造、化粧品&パーソナルケア、医療機器、消費財)分析、地域別分析、競争状況、企業情報など、以下の項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の有効性試験市場規模:サービスタイプ別(抗菌/防腐有効性試験、消毒有効性試験)
・世界の有効性試験市場規模:用途別(医薬品製造、化粧品&パーソナルケア、医療機器、消費財)
・世界の有効性試験市場規模:地域別
・競争状況
・企業情報
❖ レポートの概要 ❖

“The global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period.”
The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach. The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market.

“By method type, the traditional test method accounted for the largest share of the antimicrobial/preservative testing market”
Traditional testing methods generally require microbial assays at multiple test points over extended periods of time. Test durations typically range from a minimum of 28 days to 12 or more weeks. Because standard microbiological techniques similar to those employed in longer-term generic challenge protocols are involved, no special equipment or training is necessary to perform the assay. In fact, this accelerated double challenge (ADC) assay is currently being used in its basic form or in variations at numerous laboratories for a variety of applications.

“The pharmaceutical manufacturing application segment will grow at the highest rate during the forecast period.”
On the basis of application, the efficacy testing market is segmented into pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications. In 2021, pharmaceutical manufacturing applications were the largest product segment in the market. Growth in this market can be attributed to the increasing R&D manufactures by leading pharmaceutical companies, government support, growth of the pharmaceutical industry, and a growing focus on patient safety.

“The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020–2027).”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing government expenditure on healthcare, rising geriatric population, growing consumer health awareness, increasing incidence of chronic diseases thereby being responsible for the growth of pharmaceutical products in this region, and the increasing number of pharmaceutical companies that are establishing manufacturing facilities in APAC countries.

“North America: the largest share of the efficacy testing market”
North America accounted for the largest share of the efficacy testing market. Factors such as the presence of a well established pharmaceutical industry in the region, the high R&D expenditure, a strong presence of major service providers, and rising outsourcing of analytical testing (including efficacy testing) by pharmaceutical and cosmetic companies in the region are the major factors driving the market growth.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— Executives- 25%, CXOs- 20%, Managers – 55%
• By Region— North America – 50%, Europe – 20%, APAC – 20%, RoW- 10%

The key players operating in the efficacy testing market are Charles River Laboratories (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek Group (UK), Nelson Laboratories, LLC (a Sotera Health company, US), Microbac Laboratories, Inc. (US), Almac Group (UK), North American Science Associates, Inc. (US), Toxikon (US), Pacific Biolabs (US), MSL Solution Providers (UK), Intertek Group PLC (UK), Accugen Laboratories, Inc. (US), Consumer Product Testing Company (US), Lucideon (UK), BioScience Laboratories, Inc. (US), ALS Limited (Australia), Microchem Laboratory (US), Oxford Biosciences Ltd. (UK), Abbott Analytical (Australia), Helvic Laboratories (a Tentamus Company, UK), Honeyman Group Limited (UK), Danish Technological Institute (DTI, Denmark), and BluTest Laboratories Limited (UK).

Research Coverage:
The report segments the efficacy testing market based on region (Asia Pacific, Europe, North America, and RoW), service type (disinfectant efficacy testing and antimicrobial/preservative efficacy testing), application (pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications).
The report also provides a comprehensive review of market drivers, challenges, and opportunities in the efficacy testing market

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the efficacy testing market and provides them information on key market drivers, challenges, and opportunities.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the efficacy testing market. The report analyzes the market based on the service type, application, and region.
• Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and service/product launches in the efficacy testing market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of efficacy testing solutions across regions.
• Market Diversification: Exhaustive information about products/ services, untapped regions, recent developments, and investments in the efficacy testing market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the efficacy testing market.

❖ レポートの目次 ❖

1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.3 MARKET SCOPE 25
1.3.1 MARKETS COVERED 25
1.3.2 YEARS CONSIDERED 26
1.4 CURRENCY 26
1.5 LIMITATIONS 26
1.6 STAKEHOLDERS 27
1.7 SUMMARY OF CHANGES 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
2.1.1 SECONDARY DATA 28
2.1.2 PRIMARY DATA 28
2.1.2.1 Breakdown of primary sources 29
FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 29
2.1.2.2 Key industry insights 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 30
FIGURE 3 EFFICACY TESTING MARKET: FINAL CAGR PROJECTIONS 31
FIGURE 4 EFFICACY TESTING MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 32
FIGURE 5 EFFICACY TESTING MARKET: SEGMENTAL ASSESSMENT 33
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
FIGURE 6 DATA TRIANGULATION METHODOLOGY 34
2.4 MARKET RANKING ANALYSIS 35
2.5 RESEARCH ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
FIGURE 7 EFFICACY TESTING MARKET, BY SERVICE TYPE,
2022 VS. 2027 (USD MILLION) 36
FIGURE 8 EFFICACY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 37
FIGURE 9 REGIONAL SNAPSHOT OF EFFICACY TESTING MARKET 37

4 PREMIUM INSIGHTS 39
4.1 EFFICACY TESTING MARKET OVERVIEW 39
FIGURE 10 GROWING PREFERENCE FOR OUTSOURCING EFFICACY TESTING TO DRIVE MARKET GROWTH 39
4.2 ASIA PACIFIC: EFFICACY TESTING MARKET, BY APPLICATION AND COUNTRY (2021) 40
FIGURE 11 PHARMACEUTICAL MANUFACTURING APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 40
4.3 GEOGRAPHICAL SNAPSHOT OF EFFICACY TESTING MARKET 41
FIGURE 12 CHINA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027 41
4.4 EFFICACY TESTING MARKET, BY REGION 41
FIGURE 13 NORTH AMERICA TO DOMINATE MARKET IN 2027 41
4.5 EFFICACY TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS 42
FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 EFFICACY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 DRIVERS 44
5.2.1.1 Increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability 44
5.2.1.1.1 Growing focus on contamination control 44
5.2.1.1.2 Increasing concerns over product stability 44
5.2.1.2 Growing preference for outsourcing efficacy testing 44
5.2.1.3 Rising adoption of quality by design approach 45
5.2.1.4 Stringent regulations for use of surface disinfectants 45
5.2.1.5 Growing awareness of sanitization and hygiene due to spread of COVID-19 46
5.2.2 RESTRAINTS 46
5.2.2.1 Adverse effects of chemical disinfectants 46
5.2.3 OPPORTUNITIES 47
5.2.3.1 Emerging countries in Asia Pacific 47
5.2.4 CHALLENGES 47
5.2.4.1 Time-consuming process 47
5.3 REGULATORY ANALYSIS 47
5.3.1 DISINFECTANT EFFICACY TESTING 48
5.3.2 ANTIMICROBIAL EFFICACY TESTING 48
5.4 IMPACT OF COVID-19 ON EFFICACY TESTING SERVICES 49
5.5 PRICING ANALYSIS 49
TABLE 1 PRICE OF SURFACE DISINFECTANT PRODUCTS (2022) 49
5.6 PATENT ANALYSIS 51
5.7 TRADE ANALYSIS 51
5.7.1 TRADE ANALYSIS FOR DISINFECTANTS 51
TABLE 2 IMPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 51
TABLE 3 EXPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 52
5.8 VALUE CHAIN ANALYSIS 52
FIGURE 16 VALUE CHAIN ANALYSIS: EFFICACY TESTING MARKET 52
5.9 ECOSYSTEM ANALYSIS 53
FIGURE 17 SURFACE DISINFECTANTS MARKET: ECOSYSTEM ANALYSIS 53
TABLE 4 ROLE IN ECOSYSTEM 54
5.10 PORTER’S FIVE FORCES ANALYSIS 55
TABLE 5 EFFICACY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 55
5.10.1 THREAT OF NEW ENTRANTS 55
5.10.2 THREAT OF SUBSTITUTES 55
5.10.3 BARGAINING POWER OF BUYERS 55
5.10.4 BARGAINING POWER OF SUPPLIERS 55
5.10.5 DEGREE OF COMPETITION 56
5.11 TECHNOLOGY ANALYSIS 56
6 EFFICACY TESTING MARKET, BY SERVICE TYPE 57
6.1 INTRODUCTION 58
TABLE 6 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 58
6.2 DISINFECTANT EFFICACY TESTING 58
TABLE 7 DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 58
TABLE 8 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
TABLE 9 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
TABLE 10 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59
TABLE 11 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 12 DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 60
6.2.1 SURFACE TEST METHOD 60
6.2.1.1 Surface test method segment to account for larger share of disinfectant efficacy testing market 60
TABLE 13 SURFACE TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 61
TABLE 14 NORTH AMERICA: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61
TABLE 15 EUROPE: SURFACE TEST METHOD MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 61
TABLE 16 APAC: SURFACE TEST METHOD MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 62
6.2.2 SUSPENSION TEST METHOD 62
6.2.2.1 Suspension test method is typically performed by researchers during development stage of disinfectants 62
TABLE 17 SUSPENSION TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 62
TABLE 18 NORTH AMERICA: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63
TABLE 19 EUROPE: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63
TABLE 20 APAC: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63
6.3 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING 64
TABLE 21 EUROFINS SCIENTIFIC AET TEST PROTOCOL 64
TABLE 22 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 64
TABLE 23 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 24 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 25 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65
TABLE 26 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 66
TABLE 27 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 66
6.3.1 TRADITIONAL TEST METHOD 66
6.3.1.1 Traditional test method segment to dominate AET/PET market 66
TABLE 28 TRADITIONAL TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67
6.3.2 RAPID TEST METHOD 67
6.3.2.1 Regulatory uncertainties restraining adoption of rapid microbial methods 67
TABLE 29 RAPID TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67
7 EFFICACY TESTING MARKET, BY APPLICATION 68
7.1 INTRODUCTION 69
TABLE 30 EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 69
7.2 PHARMACEUTICAL MANUFACTURING APPLICATIONS 69
7.2.1 INCREASING FOCUS ON ENSURING QUALITY OF DRUGS TO DRIVE SEGMENT GROWTH 69
TABLE 31 EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 32 NORTH AMERICA: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 33 EUROPE: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 34 APAC: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 71
7.3 COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS 71
7.3.1 EFFICACY TESTING IS AN ESSENTIAL PART OF STABILITY TESTING REGIMEN OF COSMETICS 71
TABLE 35 EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 36 NORTH AMERICA: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 37 EUROPE: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 38 APAC: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72
7.4 CONSUMER PRODUCT APPLICATIONS 73
7.4.1 GROWING FOCUS ON HEALTHY ENVIRONMENT IN HOMES AND INDUSTRIAL FACILITIES TO DRIVE SEGMENT GROWTH 73
TABLE 39 EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 40 NORTH AMERICA: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 41 EUROPE: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 42 APAC: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74
7.5 MEDICAL DEVICE APPLICATIONS 74
7.5.1 IMPOSITION OF STRINGENT GOVERNMENT REGULATIONS TO DRIVE SEGMENT GROWTH 74
TABLE 43 EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 44 NORTH AMERICA: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 45 EUROPE: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 46 APAC: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76
8 EFFICACY TESTING MARKET, BY REGION 77
8.1 INTRODUCTION 78
TABLE 47 EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 78
8.2 NORTH AMERICA 78
FIGURE 18 NORTH AMERICA: EFFICACY TESTING MARKET SNAPSHOT 79
TABLE 48 NORTH AMERICA: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 49 NORTH AMERICA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 80
TABLE 50 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80
TABLE 51 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80
TABLE 52 NORTH AMERICA: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 81
8.2.1 US 81
8.2.1.1 US to dominate North American efficacy testing market during forecast period 81
TABLE 53 US: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 81
TABLE 54 US: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 82
TABLE 55 US: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 82
8.2.2 CANADA 82
8.2.2.1 Government initiatives to drive market growth in Canada 82
TABLE 56 CANADA: EFFICACY TESTING MARKET, BY SERVICE TYPE,
2020–2027 (USD MILLION) 83
TABLE 57 CANADA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 83
TABLE 58 CANADA: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 83
8.3 EUROPE 84
TABLE 59 EUROPE: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 60 EUROPE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 84
TABLE 61 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85
TABLE 62 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85
TABLE 63 EUROPE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85
8.3.1 GERMANY 86
8.3.1.1 Germany to account for largest share in European market 86
TABLE 64 GERMANY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 86
TABLE 65 GERMANY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 86
TABLE 66 GERMANY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86
8.3.2 FRANCE 87
8.3.2.1 High demand for cosmetics in France to drive market growth 87
TABLE 67 FRANCE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 87
TABLE 68 FRANCE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 87
TABLE 69 FRANCE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88

8.3.3 UK 88
8.3.3.1 Efficacy testing market in UK is primarily driven by enforcement of regulatory and industry standards 88
TABLE 70 UK: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 88
TABLE 71 UK: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 89
TABLE 72 UK: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89
8.3.4 ITALY 89
8.3.4.1 Increasing pharmaceutical production in Italy to drive market growth 89
TABLE 73 ITALY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 90
TABLE 74 ITALY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 90
TABLE 75 ITALY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 90
8.3.5 SPAIN 90
8.3.5.1 Rising R&D expenditure to boost market growth in Spain 90
TABLE 76 SPAIN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 91
TABLE 77 SPAIN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 91
TABLE 78 SPAIN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91
8.3.6 REST OF EUROPE 92
TABLE 79 ROE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 92
TABLE 80 ROE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 92
TABLE 81 ROE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 92
8.4 ASIA PACIFIC 93
FIGURE 19 ASIA PACIFIC: EFFICACY TESTING MARKET SNAPSHOT 93
TABLE 82 APAC: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 83 APAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 94
TABLE 84 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94
TABLE 85 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94
TABLE 86 APAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95
8.4.1 CHINA 95
8.4.1.1 China to dominate Asia Pacific market 95
TABLE 87 CHINA: EFFICACY TESTING MARKET, BY SERVICE TYPE,
2020–2027 (USD MILLION) 95
TABLE 88 CHINA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 96
TABLE 89 CHINA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
8.4.2 JAPAN 96
8.4.2.1 Rising R&D investments to drive market growth in Japan 96
TABLE 90 JAPAN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 96
TABLE 91 JAPAN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 97
TABLE 92 JAPAN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 97
8.4.3 INDIA 97
8.4.3.1 Growing pharmaceutical industry in India to drive market growth 97
TABLE 93 INDIA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 98
TABLE 94 INDIA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 98
TABLE 95 INDIA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
8.4.4 REST OF ASIA PACIFIC 98
TABLE 96 ROAPAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 99
TABLE 97 ROAPAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 99
TABLE 98 ROAPAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99
8.5 REST OF THE WORLD 100
TABLE 99 ROW: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 100
TABLE 100 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100
TABLE 101 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100
TABLE 102 ROW: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
TABLE 103 ROW: EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 101
8.5.1 LATIN AMERICA 101
8.5.1.1 Increasing pharmaceutical R&D expenditure to drive market growth in Latin America 101
TABLE 104 LATAM: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 101
TABLE 105 LATAM: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102
8.5.2 MIDDLE EAST AND AFRICA 102
8.5.2.1 UAE has emerged as key market in MEA region 102
TABLE 106 MEA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 102
TABLE 107 MEA: EFFICACY TESTING MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 103
9 COMPETITIVE LANDSCAPE 104
9.1 OVERVIEW 104
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 105
FIGURE 20 KEY DEVELOPMENTS IN EFFICACY TESTING MARKET, 2019–2022 105
9.3 MARKET SHARE ANALYSIS 106
FIGURE 21 EFFICACY TESTING MARKET SHARE, BY KEY PLAYER, 2021 106
TABLE 108 EFFICACY TESTING MARKET: DEGREE OF COMPETITION 106
9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 107
9.5 COMPANY EVALUATION QUADRANT 108
9.5.1 STARS 108
9.5.2 EMERGING LEADERS 108
9.5.3 PERVASIVE PLAYERS 108
9.5.4 PARTICIPANTS 108
9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 110
9.6.1 PROGRESSIVE COMPANIES 110
9.6.2 STARTING BLOCKS 110
9.6.3 RESPONSIVE COMPANIES 110
9.6.4 DYNAMIC COMPANIES 110
9.7 FOOTPRINT ANALYSIS OF COMPANIES 112
9.7.1 SERVICE FOOTPRINT OF COMPANIES 112
TABLE 109 SERVICE FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 112
9.7.2 REGIONAL FOOTPRINT OF COMPANIES 113
TABLE 110 REGIONAL FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 113
9.8 COMPETITIVE SCENARIO 114
TABLE 111 PRODUCT LAUNCHES 114
TABLE 112 DEALS 114
TABLE 113 OTHER DEVELOPMENTS 115
10 COMPANY PROFILES 116
10.1 EFFICACY TESTING SERVICE PROVIDERS 116
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 EUROFINS SCIENTIFIC 116
TABLE 114 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 116
FIGURE 25 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 117
10.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 119
TABLE 115 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 119
FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.:
COMPANY SNAPSHOT (2021) 120

10.1.3 WUXI APPTEC 122
TABLE 116 WUXI APPTEC: BUSINESS OVERVIEW 122
FIGURE 27 WUXI APPTEC: COMPANY SNAPSHOT (2021) 123
10.1.4 SGS SA 125
TABLE 117 SGS SA: BUSINESS OVERVIEW 125
10.1.5 INTERTEK GROUP PLC 127
TABLE 118 INTERTEK GROUP PLC: BUSINESS OVERVIEW 127
FIGURE 28 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021) 128
10.1.6 MICROCHEM LABORATORY 130
TABLE 119 MICROCHEM LABORATORY: BUSINESS OVERVIEW 130
10.1.7 ACCUGEN LABORATORIES, INC. 131
TABLE 120 ACCUGEN LABORATORIES, INC.: BUSINESS OVERVIEW 131
10.1.8 PACIFIC BIOLABS 133
TABLE 121 PACIFIC BIOLABS: BUSINESS OVERVIEW 133
10.1.9 NORTH AMERICAN SCIENCE ASSOCIATES 134
TABLE 122 NORTH AMERICAN SCIENCE ASSOCIATES: BUSINESS OVERVIEW 134
10.1.10 TOXIKON 135
TABLE 123 TOXIKON: BUSINESS OVERVIEW 135
10.1.11 BIOSCIENCE LABORATORIES, INC. 136
TABLE 124 BIOSCIENCE LABORATORIES, INC.: BUSINESS OVERVIEW 136
10.1.12 CONSUMER PRODUCT TESTING COMPANY (CPTC) 137
TABLE 125 CONSUMER PRODUCT TESTING COMPANY (CPTC): BUSINESS OVERVIEW 137
10.1.13 ALMAC GROUP 138
TABLE 126 ALMAC GROUP: BUSINESS OVERVIEW 138
10.1.14 MSL SOLUTION PROVIDERS 139
TABLE 127 MSL SOLUTION PROVIDERS: BUSINESS OVERVIEW 139
10.1.15 NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY) 140
TABLE 128 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW 140
10.1.16 ALS LIMITED 141
TABLE 129 ALS LIMITED: BUSINESS OVERVIEW 141
10.1.17 ABBOTT ANALYTICAL 142
TABLE 130 ABBOTT ANALYTICAL: BUSINESS OVERVIEW 142
10.1.18 BLUTEST LABORATORIES LIMITED 143
TABLE 131 BLUTEST LABORATORIES LIMITED: BUSINESS OVERVIEW 143
10.1.19 LUCIDEON 144
TABLE 132 LUCIDEON: BUSINESS OVERVIEW 144
10.1.20 HELVIC LABORATORIES (A TENTAMUS COMPANY) 145
TABLE 133 HELVIC LABORATORIES: BUSINESS OVERVIEW 145
10.2 MANUFACTURERS OF DISINFECTANTS 146
10.2.1 PROCTER & GAMBLE 146
TABLE 134 PROCTER & GAMBLE: BUSINESS OVERVIEW 146
FIGURE 29 PROCTER & GAMBLE: COMPANY SNAPSHOT (2021) 147
10.2.2 THE CLOROX COMPANY 149
TABLE 135 THE CLOROX COMPANY: BUSINESS OVERVIEW 149
FIGURE 30 THE CLOROX COMPANY: COMPANY SNAPSHOT (2021) 149
10.2.3 3M 152
TABLE 136 3M: BUSINESS OVERVIEW 152
FIGURE 31 3M: COMPANY SNAPSHOT (2021) 153
10.2.4 RECKITT BENCKISER GROUP PLC 155
TABLE 137 RECKITT BENCKISER GROUP PLC: BUSINESS OVERVIEW 155
FIGURE 32 RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT (2021) 156
10.2.5 ECOLAB 158
TABLE 138 ECOLAB: BUSINESS OVERVIEW 158
FIGURE 33 ECOLAB: COMPANY SNAPSHOT (2021) 159
10.2.6 STERIS 162
TABLE 139 STERIS: BUSINESS OVERVIEW 162
FIGURE 34 STERIS: COMPANY SNAPSHOT (2021) 163
10.2.7 CANTEL MEDICAL 165
TABLE 140 CANTEL MEDICAL: BUSINESS OVERVIEW 165
FIGURE 35 CANTEL MEDICAL: COMPANY SNAPSHOT (2021) 166
10.2.8 DIVERSEY HOLDINGS LTD. 168
TABLE 141 DIVERSEY HOLDINGS LTD.: BUSINESS OVERVIEW 168
FIGURE 36 DIVERSEY HOLDINGS LTD.: COMPANY SNAPSHOT (2021) 168
10.2.9 CARROLLCLEAN 171
TABLE 142 CARROLLCLEAN: BUSINESS OVERVIEW 171
10.2.10 PAUL HARTMANN AG 173
TABLE 143 PAUL HARTMANN AG: BUSINESS OVERVIEW 173
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 175
11.1 DISCUSSION GUIDE 175
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 177
11.3 AVAILABLE CUSTOMIZATIONS 179
11.4 RELATED REPORTS 180
11.5 AUTHOR DETAILS 181



★調査レポート[世界の有効性試験市場(~2027年):サービスタイプ別(抗菌/防腐有効性試験、消毒有効性試験)、用途別(製薬、化粧品&パーソナルケア、医療機器、消費財)、地域別] (コード:BT5932-22)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の有効性試験市場(~2027年):サービスタイプ別(抗菌/防腐有効性試験、消毒有効性試験)、用途別(製薬、化粧品&パーソナルケア、医療機器、消費財)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆